RecruitingNCT07159750
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Enrollment
700 participants
Start Date
Jan 2, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Migraine diagnosis according to ICHD-III.
- Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
- Signature of informed consent.
Exclusion Criteria2
- Presence of headache different from migraine.
- Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCGRP antibody or gepant
Patients will start anti-CGRP or its receptor antibody or gepants
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07159750
Related Trials
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
NCT056697031 location
BE WELL With Migraine: Brain Education and WELLness With Migraine
NCT059875923 locations
Aerobic Exercise and Its Impact on Sensory, Musculoskeletal, and Psychosocial Aspects in Migraine
NCT067164891 location
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
NCT066241372 locations
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700106 locations